Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Other ASCO 2018 Highlights – It’s Not All IO

Executive Summary

The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET. 

Advertisement

Related Content

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
Under The Radar: Potential Small Cap Takeover Targets
Loxo Edges Closer To Commercial Market With Larotrectinib, But Diagnostic Challenge Persists
More Deals Like Loxo On The Cards As Bayer Ups Ante In Oncology
Rolontis Leads Hanmi’s Global Ambitions As ADVANCE Phase III Endpoint Met
Agios' IDH Inhibitors Show Their Mettle At ASH
Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice
Pfizer drug fails in two Phase III lung cancer studies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123109

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel